Superior Efficacy of Midostaurin Over Cladribine in Advanced Systemic Mastocytosis: A Registry-Based Analysis.

Johannes LübkeJuliana SchwaabNicole NaumannHans-Peter HornyChristel WeißGeorgia MetzgerothSebastian KreilNicholas C P CrossKarl SotlarAlice FabariusWolf-Karsten HofmannPeter ValentJason GotlibMohamad JawharAndreas Reiter

Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)

In this registry-based analysis, midostaurin revealed superior efficacy over cladribine in patients with AdvSM. In midostaurin-treated patients, the combination of baseline MARS and molecular response provided a compelling three-tier risk categorization (MARSv2.0) for OS.

Keyphrases

end stage renal disease
newly diagnosed
chronic kidney disease
ejection fraction
peritoneal dialysis